MCPH1/BRIT1 deficiency is therefore a regulator for HCC growth and using olaparib and/or BEZ235 as a treatment is highly sensitive in MCPH1/BRIT1 deficient HCC. Here, MCPH1 is linked to hepatocellular carcinoma.